MK-8189 (deudomperidone)
Vasomotor symptoms due to menopause
Phase 3Active
Key Facts
About Organon
Organon's mission is to improve the health of women throughout their lives by addressing critical gaps in reproductive health, contraception, fertility, and menopause. The company has achieved immediate global scale with a portfolio in over 140 markets, leveraging its heritage brands and deep commercial expertise. Its strategy focuses on maximizing the value of its established therapeutic portfolio, expanding access to biosimilars, and advancing a targeted pipeline in women's health to drive sustainable growth.
View full company profileTherapeutic Areas
Other Vasomotor symptoms due to menopause Drugs
| Drug | Company | Phase |
|---|---|---|
| Fezolinetant | Astellas Pharma | Approved |